Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTYX vs RLAY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTYX Captures Overall Composite Edge (50.4 HOLD vs 50.0 HOLD), While RLAY Leads 3–1 on Growth & Valuation Pillars

VTYX Overall Winner 6-Pillar Tally: VTYX 1 – 3 RLAY (2 Tie) Matrix Metrics: VTYX 4 – 3 RLAY

As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Relay Therapeutics, Inc. (RLAY) on higher Unified Composite conviction (50.4/100 HOLD vs. 50.0/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality), while RLAY wins 3–1 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus RLAY at $17.46 (N/M Forward P/E, -3094.6% operating margin).

  • Growth vs. Quality Trade-Off: VTYX earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. RLAY 50.0/100 HOLD) and 2.07β · 2% Vol risk profile, whereas RLAY leads top-line expansion (-48.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile RLAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTYX vs RLAY
VTYX NASDAQ Head-to-Head Winner
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.07β · 2% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.0% over 20 days), RSI 71
RSI-14: 70.7 · SMA20: $13.96 · SMA50: $12.72
RLAY NASDAQ
Relay Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$17.46
-3.48% 1D
Market Cap $4.0B
TTM Revenue $10M
Forward P/E N/M
Beta / 30D Vol 1.70β · 78% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 48.0 Fund 55.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 45
RSI-14: 44.8 · SMA20: $18.49 · SMA50: $18.34

6-Pillar Scorecard Institutional Category Breakdown (VTYX 1 – 3 RLAY)

Columns: Metric · VTYX · RLAY
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale RLAY
Revenue Growth (YoY) +0.0% -48.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $10M
Market Cap $1.0B $4.0B
3. Profitability & Quality VTYX
Gross Margin N/A N/A
Operating Margin 0.0% -3094.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -45.4% -41.2%
4. Balance Sheet & Cash Flow RLAY
Cash Generation (TTM) N/A -$214M
Cash Flow Margin N/A N/A
Net Cash / Leverage $2.68 Book/Sh · -45.4% ROE $97M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RLAY
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 0.5% (<1st %ile) 68.4% (6th %ile)
Put/Call OI Skew N/A 0.99x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTYX (4) vs RLAY (3)
Institutional Metric VTYX RLAY Criterion Row Edge
Market Capitalization
Scale
$1.0B $4.0B Larger Scale RLAY
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -48.3% Higher Growth VTYX
Operating Margin (TTM)
Profitability
0.0% -3094.6% Higher Margin VTYX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-45.4% -41.2% Higher ROE RLAY
52-Week Range Position
Momentum
55% ($1–$25) 75% ($6–$21) Stronger Trend RLAY
Beta / 30D Volatility
Risk Regime
2.07β · 2% Vol 1.70β · 78% Vol Lower Realized Risk VTYX
Unified Institutional Score
Composite Signal
50.4 / 100 (HOLD) 50.0 / 100 (HOLD) Higher Composite VTYX
Trailing 12M Revenue (USD)
Operating Scale
N/A $10M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($2.68 Book/Sh · -45.4% ROE) -$214M ($97M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RLAY +28.23 pp
VTYX: +0.36% · RLAY: +28.59%
3M Horizon VTYX +15.63 pp
VTYX: +40.0% · RLAY: +24.37%
6M Horizon RLAY +6.11 pp
VTYX: +46.6% · RLAY: +52.71%
1Y Horizon RLAY +6.11 pp
VTYX: +46.6% · RLAY: +52.71%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs RLAY. Trailing 12-month operating profitability (VTYX 0.0% vs RLAY -3094.6%) and valuation multiples (VTYX N/M vs RLAY N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VTYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.4% · N/M
RLAY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10M
Gross MarginN/A
Op. Margin-3094.6%
ROE / Fwd P/E-41.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RLAY CONSOLIDATION
101d in phase · OBV NEUTRAL
Current IV 68.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.99x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RLAY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTYX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RLAY Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.0B market capitalization and -3094.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTYX vs RLAY Key Questions & Quantitative Answers

As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Relay Therapeutics, Inc. (RLAY) on higher Unified Composite conviction (50.4/100 HOLD vs. 50.0/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality), while RLAY wins 3–1 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus RLAY at $17.46 (N/M Forward P/E, -3094.6% operating margin). Growth vs. Quality Trade-Off: VTYX earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. RLAY 50.0/100 HOLD) and 2.07β · 2% Vol risk profile, whereas RLAY leads top-line expansion (-48.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile RLAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RLAY leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RLAY at -48.3% YoY revenue growth and +0.0% YoY earnings growth on $10M TTM revenue (N/A gross margin, -3094.6% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus $10M for RLAY. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RLAY.

VTYX and RLAY trade at balanced relative valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas RLAY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus RLAY (-41.2% ROE) capital efficiency.

In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, RLAY carries 68.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.99x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.70β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.